NCT03670823 is a clinical trial of SIEMENS PRISMA MRI in Major Depression, sponsored by ElMindA Ltd.

Who is sponsoring NCT03670823?

NCT03670823 is sponsored by ElMindA Ltd.

What drugs are being tested in NCT03670823?

Interventions in NCT03670823: SIEMENS PRISMA MRI.

What condition does NCT03670823 study?

NCT03670823 studies Major Depression.

Is NCT03670823 still recruiting?

NCT03670823 is currently status unknown. Last updated 7 June 2019.

Last reviewed 2019-06-07 · How we verify

NCT03670823

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prediction of SSRI Treatment in Major Depression.

Status unknown Last updated 7 June 2019

What this trial tests

trial testing SIEMENS PRISMA MRI in Major Depression in 100 participants. Status unknown.

Timeline

1 March 2019

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	ElMindA Ltd
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 March 2019
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across Israel

Drugs / interventions tested

SIEMENS PRISMA MRI

Conditions studied

Major Depression — all drugs for Major Depression →

Sponsor

ElMindA Ltd

Who can join

Adults 18 to 65, any sex, with Major Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project will combine the data collected from EEG, Eye tracking, structural and functional MRI scans and neuropsychological performance from patients with major depression receiving SSRI treatment. The purpose of this research is to predict the success of the SSRI treatment and to categorize patients into sub-groups according to similar patterns of brain activation to personalize treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Major Depression

Currently open trials in the same condition.

NCT07031817 — Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Di · NA · recruiting
NCT07184697 — Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. · NA · active not recruiting
NCT07463911 — Treatment Response In ECT Patients · active not recruiting
NCT06763081 — Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation · recruiting
NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting

Other ElMindA Ltd trials

Trials by the same sponsor.

NCT03699514 — Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology · unknown
NCT03265925 — Brain Network Activation Analysis in Epilepsy · completed
NCT03265912 — Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment · completed
NCT02878577 — Monitoring the Alterations That Occur in the Brain Following Traumatic Brain Injury · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03670823 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ElMindA Ltd
Last refreshed: 7 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03670823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing